Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalantercept in Recurrent or Persistent Endometrial Carcinoma
NCT01642082Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Sep 2012
- Primary completion
- Jan 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalantercept in endometrial carcinoma, sponsored by GOG Foundation. Primary endpoints: Objective Tumor Response (Complete or Partial) at 6 months, Progression-Free Survival at 6 Months and 1 more. Started Sep 2012; status: completed.
02
Drugs
dalantercept
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT01642082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01642082.